COPD

The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?

Individualizing COPD Treatment to Improve Adherence and Overall Outcomes

Continuing education for pharmacists.

Class of Cancer Drugs May Have Potential as Chronic Obstructive Pulmonary Disease Treatment

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

High Levels of Ozone, Wood Burning Linked to Chronic Obstructive Pulmonary Disease Among Smokers, Nonsmokers

Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.

Digital Health Tool Improves Health Outcomes for Patients with COPD

The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.

COPD Awareness Month: The More You Learn, The Better You Breathe

Each November, members of the chronic obstructive pulmonary disease (COPD) community come together to focus on increasing awareness of the respiratory condition.

Studies Test Revefenacin Safety, Efficacy in Patients with COPD

Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.

Multidose Inhaler Launched for Patients with COPD

Starting on October 21^st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.

Researcher Awarded $7.5 Million in Funding for COPD Research

A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.

Nanoparticles in Mucus a Possible Indicator of COPD

Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.

Triple Combination Therapy Shows Positive Results for Patients with COPD

The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).

New Research Links Yoga to Improved Pulmonary Function in Patients with COPD

Published in Clinical Rehabilitation, investigators found that breathing techniques commonly utilized in yoga may be an effective adjunct intervention for individuals with COPD.

Increased COPD Prevalence Linked with Arthritis

A recent study found the prevalence of COPD was nearly 50% higher among patients with arthritis compared with those without arthritis, even after adjusting for sociodemographic characteristics, risk behaviors, frequent distress, and asthma status.

The Pharmacy Times® COPD condition center provides a source of all the latest clinical information, with articles covering an array of progressive lung diseases, like emphysema, chronic bronchitis, and refractory asthma, as well as the robust pipeline of novel COPD therapies. It also serves as a hub of information and news from the upcoming and ongoing conferences and annual meetings of pulmonologists, including pivotal coverage right from the floor.

Among its other resources are a wealth of videos including interviews with thought leaders and experts in COPD, and moderated Peer Exchange panel discussions about the best practices and key methods for treating complex cases, utilizing the newest therapies, examining the issues and challenges of treating the disease, and much more.